Pakistan, June 24 -- The United States has supplied doses of an experimental Ebola treatment to support clinical trials in the Democratic Republic of Congo (DRC), as health authorities work to contain a growing outbreak of the deadly virus.

According to US health officials, the antibody-based treatment developed by Mapp Biopharmaceutical will be used in ongoing clinical studies and for compassionate treatment of eligible patients in affected areas. The move represents a significant expansion of access to the drug, which had previously been available mainly within the United States.

Officials from the US Department of Health and Human Services said the initiative aims to generate scientific data that could support future regulatory appro...